CDKN2A and central nervous system cancer: In one case who was treated with TTFields for 67 months, tumor recurrence with histological characteristics of lower grade glioma was observed, exhibiting TERT promoter mutation, CDKN2A homozygous deletion, and EGFR amplification without IDH mutation in lower TTFields LMiPD area along with local recurrence.